Display Settings:

Format

Send to:

Choose Destination

    Ann Intern Med. 2000 Sep 19;133(6):464-70.

    Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

    Ellenberg SS, Temple R.

    Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA.

    Comment in:

    Placebo controls are commonly used in clinical trials of investigational treatments because they have important advantages. In recent years, some have criticized the use of placebo-controlled trials when effective alternative therapy exists, regardless of the expected effect of the therapy. In part 1 of this paper, ethical arguments are addressed and the interpretive problems inherent in the use of active-control equivalence trials to establish efficacy of a new treatment are clarified. However, uncertainties may complicate decisions about appropriate use of placebo controls in some situations. Part 2 discusses more fully the ethical considerations for using placebo controls in particular medical settings. The value and relevance of placebo-controlled trials of new agents in situations in which proven effective therapy is available are also explored.

    PMID: 10975965 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read